10-Q: Tarsus Pharmaceuticals Reports Strong Q3 XDEMVY Sales

Tarsus Pharmaceuticals announced significant revenue growth for its lead product XDEMVY in Q3 2025, alongside continued operating losses and strategic pipeline advancements.

Summary

• Net product sales for XDEMVY increased by 147% year-over-year to $118.7 million for the three months ended September 30, 2025, compared to $48.1 million in the prior year period.
• For the nine months ended September 30, 2025, net product sales reached $299.7 million, up from $113.7 million in the same period of 2024.
• The company delivered approximately 103,000 bottles of XDEMVY to patients in Q3 2025, a significant increase from 41,400 bottles in Q3 2024.
• Net loss improved to $(12.6) million for Q3 2025, compared to $(23.4) million for Q3 2024.
• The net loss for the nine months ended September 30, 2025, was $(58.0) million, an improvement from $(92.4) million in the corresponding period of 2024.
• XDEMVY has achieved broad, high-quality payer coverage, with over 90% of commercial, Medicare, and Medicaid lives covered, resulting in a gross-to-net discount of 44.7%.
• Over 20,000 Eye Care Professionals (ECPs) have written multiple prescriptions for XDEMVY, indicating growing confidence and integration into clinical practice.
• The number of ECPs prescribing more than one bottle per week increased by approximately 30% compared to Q2 2025.
• Cash, cash equivalents, and marketable securities totaled $401.8 million as of September 30, 2025.
• Research and development expenses increased by $4.2 million in Q3 2025 and $9.8 million for the nine months ended September 30, 2025, primarily due to increased payroll, personnel costs, and early-stage programs.
• Selling, general and administrative expenses increased by $50.7 million in Q3 2025 and $128.4 million for the nine months ended September 30, 2025, driven by commercial expansion, marketing costs (including direct-to-consumer advertising), and increased variable costs.
• The company's accumulated deficit was $(418.3) million as of September 30, 2025.
• Positive topline results were announced for the Galatea trial (TP-04 for rosacea) in February 2024 and the Carpo trial (TP-05 for Lyme disease) in February 2024.
• A Phase 2 study for TP-04 (ocular rosacea) is planned to initiate in December 2025, with topline results expected by year-end 2026.
• The FDA agreed to the proposed approach for a Phase 2b clinical trial of TP-05 (Lyme disease), with planned initiation expected in 2026.
• A potential European regulatory submission for a preservative-free formulation of XDEMVY is expected in 2026, with approval anticipated in 2027.
• The company has one remaining $50.0 million tranche available from its 2024 Credit Facility, which may be requested on or prior to December 31, 2025.

Sentiment

Score: 7

Explanation: The company demonstrates strong commercial execution with significant revenue growth for XDEMVY and positive advancements in its pipeline candidates. However, it continues to incur substantial operating losses and relies on future capital raises, indicating a long path to sustained profitability. The overall sentiment is cautiously optimistic, reflecting good progress but ongoing financial challenges.

Positives

• Net product sales for XDEMVY increased by 147% year-over-year in Q3 2025 to $118.7 million, demonstrating strong commercial traction.
• The company delivered approximately 103,000 bottles of XDEMVY to patients in Q3 2025, indicating robust market penetration.
• Net loss significantly improved to $(12.6) million in Q3 2025 from $(23.4) million in Q3 2024, and to $(58.0) million for 9M 2025 from $(92.4) million for 9M 2024.
• XDEMVY has secured broad payer coverage, with over 90% of commercial, Medicare, and Medicaid lives covered, facilitating patient access.
• Over 20,000 Eye Care Professionals (ECPs) have written multiple prescriptions for XDEMVY, reflecting growing confidence and consistent integration into clinical practice.
• The number of ECPs prescribing more than one bottle per week increased by approximately 30% compared to the previous quarter, signaling strong adoption.
• Positive topline results were achieved in the Galatea trial for TP-04 (rosacea) and the Carpo trial for TP-05 (Lyme disease), advancing the pipeline.
• The FDA agreed to the proposed Phase 2b clinical trial approach for TP-05, providing a clear regulatory path forward.
• The company maintains a strong liquidity position with $401.8 million in cash, cash equivalents, and marketable securities as of September 30, 2025.

Negatives

• The company continues to incur significant operating losses and negative cash flows from operations since its inception, with an accumulated deficit of $(418.3) million as of September 30, 2025.
• Operating expenses, particularly selling, general and administrative costs, increased substantially due to commercial expansion and product development initiatives.
• The company is heavily dependent on the successful commercialization of XDEMVY and the development of its pipeline candidates, posing concentration risk.
• Capital requirements are difficult to predict and may necessitate additional funding, with no assurance of availability on acceptable terms.
• Estimates of market opportunities for XDEMVY and other product candidates may be smaller than anticipated, potentially limiting sales growth.
• Reliance on third parties and single-source suppliers for manufacturing increases supply chain risks.
• Clinical drug development is inherently lengthy, expensive, and risky, with uncertain timelines and outcomes.
• Uncertainty remains regarding future milestone consideration from GrandPharma under the China Out-License.

Risks

• The company has a limited operating history and a single product approved for commercial sale, XDEMVY, and has incurred significant losses and negative cash flows since inception.
• Capital requirements are difficult to predict and may change, potentially forcing delays or elimination of product development or commercialization efforts if additional funding is not obtained.
• The commercialization of XDEMVY or any future approved products may be unsuccessful, preventing the company from achieving profitability.
• Heavy dependence on the successful commercialization of XDEMVY and the development, regulatory approval, and commercialization of current and future product candidates.
• The company may not be successful in educating Eye Care Professionals (ECPs) and the market about the need for treatments for Demodex blepharitis and other targeted conditions.
• XDEMVY or other product candidates may fail to achieve market acceptance by ECPs, healthcare providers, and patients, or adequate formulary coverage, pricing, or reimbursement.
• The estimated market opportunities for XDEMVY and other product candidates may be smaller than anticipated, adversely affecting sales growth.
• Development and commercialization of products are dependent on intellectual property licensed from Elanco, and breaches or terminations of these agreements could lead to loss of rights.
• Expected expansion of development, regulatory, and operational capabilities may lead to difficulties in managing growth and disrupt operations.
• Reliance on third parties for commercial manufacturing and single-source suppliers for materials increases supply chain risks and potential for insufficient quantities or unacceptable costs.
• Clinical drug development is a lengthy, expensive, and risky process with uncertain timelines and outcomes, and earlier trial results may not predict future success.
• Any termination, suspension, or delays in clinical trials could increase costs, delay revenue generation, and adversely affect commercial prospects.
• Reliance on third parties to conduct clinical trials and research poses risks if they do not satisfactorily carry out duties or meet deadlines.
• Inability to obtain and maintain sufficient intellectual property protection or if the scope is not broad enough, competitors could commercialize similar products.
• Patent terms may be inadequate to protect the competitive position of product candidates and preclinical programs for a sufficient duration.
• Concentration of stock ownership may limit the ability of other stockholders to influence corporate matters.
• Future product candidates may cause significant adverse events, toxicities, or undesirable side effects, delaying or preventing marketing approval or leading to abandonment.
• Failure to comply with obligations under Medicaid Drug Rebate Program and other governmental pricing programs could result in penalties and fines.
• Expending limited resources on XDEMVY may lead to failure to capitalize on potentially more profitable product candidates or indications.
• Ongoing regulatory obligations and review for XDEMVY and any approved product candidates may require substantial resources and limit manufacturing and marketing.
• Improper promotion for off-label uses or misuse of products could lead to prohibitions, product liability claims, fines, and reputational harm.
• FDA may not accept data from clinical trials conducted outside the U.S., requiring additional costly and time-consuming trials.
• Managing obligations under in-license and out-license agreements may divert management time and attention.
• Interim top-line and preliminary clinical trial results may change as more data become available and are subject to audit and verification.
• Adverse developments affecting the financial services industry could impact liquidity, operations, and financial condition.
• Existing indebtedness under the 2024 Credit Facility may limit financial flexibility and adversely affect business.
• Engaging in acquisitions or strategic partnerships could disrupt business, cause dilution, reduce financial resources, or incur debt/contingent liabilities.
• Ability to use net operating loss carryforwards and certain other tax attributes may be limited.
• Adverse legislative or regulatory tax changes, such as the OBBB Act, could negatively impact financial condition.
• Reliance on trade secrets and proprietary know-how, which are difficult to trace and enforce, could harm competitive position if confidentiality is not protected.
• Claims that employees, consultants, or contractors have wrongfully used or disclosed confidential information of third parties.
• Intellectual property rights may not address all potential threats to competitive advantage.
• Involvement in lawsuits to protect or enforce patents and other intellectual property rights could be expensive, time-consuming, and unsuccessful.
• Inability to protect intellectual property rights throughout the world due to varying national laws and enforcement.
• Stock price volatility and potential decline regardless of operating performance.
• Securities or industry analysts ceasing coverage or publishing inaccurate/unfavorable research could cause stock price and trading volume to decline.
• Sales of a substantial number of shares of common stock in the public market could cause the stock price to fall.
• Delaware law and provisions in corporate documents could make a merger, tender offer, or proxy contest difficult.
• Requirements associated with being a public company increase costs and divert resources.
• Failure to maintain proper and effective internal controls could impair ability to produce accurate and timely financial statements.
• No intention to pay dividends for the foreseeable future, requiring stockholders to rely on stock appreciation for gains.
• Risk of securities class action litigation.
• Operating results may fluctuate significantly, making future results difficult to predict and potentially falling below expectations.

Future Outlook

The company expects to continue incurring operating losses for the foreseeable future but estimates its existing capital resources will be sufficient to meet projected operating expenses and liquidity needs for at least the next 12 months. It plans to fund operations using existing cash, investments, and cash generated from commercial activities, but may need to raise additional capital. Key pipeline advancements include initiating a Phase 2 study for TP-04 (ocular rosacea) in December 2025 with topline results by year-end 2026, and a Phase 2b clinical trial for TP-05 (Lyme disease) in 2026. A potential European regulatory submission for preservative-free XDEMVY is expected in 2026, with approval anticipated in 2027. The company is also in ongoing discussions with Japanese regulatory authorities for Demodex blepharitis. One remaining $50.0 million tranche from the 2024 Credit Facility is available until December 31, 2025.

Management Comments

• We are two years into launch and believe we are fundamentally changing how eye care professionals (ECPs) diagnose and treat Demodex blepharitis.
• More than 20,000 ECPs have written multiple prescriptions reflecting growing confidence and the consistent integration of XDEMVY into clinical practice.
• At the end of the third quarter of 2025, the number of ECPs prescribing more than one bottle per week increased by approximately 30% compared to the second quarter of 2025.
• We continue to believe that the best approach to get this potential prophylactic therapy [TP-05 for Lyme disease] to patients is to partner this program either prior to the planned initiation of the Phase 2b study or after the completion of the study.

Industry Context

The biopharmaceutical industry is highly competitive, with Tarsus Pharmaceuticals competing against major pharmaceutical, specialty pharmaceutical, and biotechnology companies. There is significant industry-wide interest in healthcare cost containment, quality improvement, and expanded access, leading to increased governmental scrutiny over drug pricing. Proposed EU pharmaceutical legislation reforms could reduce regulatory data protection periods, potentially accelerating generic competition. Global and geopolitical economic conditions, including conflicts and inflation, pose risks to financial markets, supply chains, and clinical trial operations. The funding levels and operational efficiency of regulatory agencies like the FDA can also impact product review and approval timelines.

Comparison to Industry Standards

• XDEMVY is the first and only FDA-approved therapeutic for Demodex blepharitis, establishing it as a definitive standard of care without direct FDA-approved competitors. Existing treatments are primarily over-the-counter or off-label remedies.
• TP-05 is noted as the only on-demand, oral tablet in development targeting ticks for Lyme disease prophylaxis, suggesting a unique market position if successful, without direct comparable projects mentioned in the filing.
• The filing mentions 'competing therapies that are or may become available' and 'existing branded, generic and off-label products' for blepharitis, but does not name specific comparable companies or projects with results for direct comparison. This highlights XDEMVY's current unique market position.

Legal Proceedings

• The company is not currently a party to any material legal proceedings.
• From time to time, the company may become involved in legal proceedings arising in the ordinary course of business.

Related Party Transactions

• In April 2024, the company purchased $3.0 million of preferred stock in a privately-held eye care company where Drs. Bobak Azamian (CEO and Chair of the Board) and William Link (Board Member) also serve as board members.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity raises, stock price volatility, and reliance on stock appreciation for returns as no dividends are expected. Concentrated ownership may limit influence on corporate matters.
• Employees: Benefits from stock-based compensation, but faces intense competition for qualified personnel and risks associated with employee misconduct.
• Customers/Patients: Gained access to XDEMVY for Demodex blepharitis, with potential for new therapies (TP-04 for ocular rosacea, TP-05 for Lyme disease). Impacted by pricing, reimbursement policies, and product liability risks.
• Suppliers/Manufacturers: Continued reliance on third-party and single-source manufacturers for XDEMVY and pipeline candidates, posing risks of supply disruptions and cost fluctuations.
• Creditors: Obligations under the 2024 Credit Facility, which is collateralized by substantially all of the company's assets, and subject to covenants that may restrict operations.

Next Steps

• Initiate a Phase 2 study for TP-04 (ocular rosacea) in December 2025, with topline results expected by year-end 2026.
• Initiate a Phase 2b clinical trial for TP-05 (Lyme disease) in 2026, following FDA agreement on the proposed approach.
• Seek a partnership for the TP-05 (Lyme disease) program, either before or after the Phase 2b study.
• Pursue potential European regulatory submission for a preservative-free formulation of XDEMVY in 2026, with anticipated approval in 2027.
• Continue communications with regulatory authorities in Japan to determine a regulatory path forward for Demodex blepharitis.
• May request the remaining $50.0 million tranche from the 2024 Credit Facility on or prior to December 31, 2025.
• Continue to commercialize XDEMVY and advance other product candidates through clinical development and regulatory processes.

Key Dates

Recommendation

Tarsus Pharmaceuticals demonstrates strong commercial momentum with XDEMVY, evidenced by significant revenue growth and increasing ECP adoption. The pipeline also shows promising advancements with positive clinical trial results for TP-04 and TP-05, and clear regulatory paths forward. However, the company continues to operate at a net loss and has an accumulated deficit, indicating that profitability is still a future objective requiring substantial additional capital. While the current cash position is solid, the need for future financing and the inherent risks of drug development and commercialization temper immediate upside potential. A 'hold' recommendation allows investors to observe continued execution on commercialization, pipeline progression, and the path to profitability without committing additional capital at this stage, as much of the positive news may already be factored into the current share price.

Keywords

Biopharmaceutical, XDEMVY, Demodex blepharitis, Ocular rosacea, Lyme disease, Lotilaner, Clinical trials, FDA approval, Commercialization, Financial results, Q3 2025, Tarsus Pharmaceuticals, TP-04, TP-05, Eye care, Infectious disease, Drug development, SEC filing, 10-Q